VENTURA COUNTY
HEALTH CARE PLAN

**Prior Authorization DRUG Guidelines**

# GANIRELIX ACETATE (Orgalutran)

Effective Date: 1/28/14

Date Developed: 1/28/14 by Catherine Sanders, MD

Last Approval Date: 1/26/16, 1/24/17, 1/22/19, 2/18/20, 2/2/21, 2/1/22, 1/31/23

(Archived: 1/1/18)

**Unarchived Date: 1/22/19 (Formulary Exclusion – For Exception Review Use Only)**

Ganirelix Acetate is a gonadotropin releasing hormone antagonist which competitively blocks the gonadotropin-release hormone receptors on the pituitary gonadotroph and transduction pathway. This suppresses gonadotropin secretion and luteinizing hormone secretion preventing ovulation until the follicles are of adequate size.

**Pre-Authorization Criteria:** Ganirelix is used to inhibit premature luteinizing hormone (LH) surges in non-pregnant women without primary ovarian failure who will undergo controlled ovarian hyper-stimulation.

**NOTE:** must be prescribed by an infertility specialist.

**Dosing: Adult:**
Adjunct to controlled ovarian hyperstimulation: SubQ: 250 mcg/day during the mid-to-late phase after initiating follicle-stimulating hormone on day 2 or 3 of cycle. Treatment should be continued daily until the day of chorionic gonadotropin administration.

**Dosing: Pediatric:**
Pediatric dosing is currently unabailable or not applicable for this drug.

**Dosing: Geriatric:**
Refer to adult dosing.

**Dosing: Renal Impairment :**
No dosage adjustment provided in manufacturer's labeling (has not been studied).

**Dosing: Hepatic Impairment:**
No dosage adjustment provided in manufacturer's labeling (has not been studied).

**Dosage Forms: U.S.:**
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Solution, Subcutaneous, as acetate:
Generic: 250 mcg/0.5 mL (0.5 mL)

Generic Equivalent Available: U.S.-Yes

**Administration:**
Administer SubQ in abdomen (around upper navel) or upper thigh; rotate injection site.

Hazardous agent; use appropriate precautions for handling and disposal (NIOSH, 2012).

**Adverse Reactions:**
Anaphylactoid reaction, fetal harm or death, ovarian hyperstimulation syndrome, abdominal pain, nausea, pelvic pain, vaginal bleeding, loac injection site reaction, headache, neutrophils increased.

**References:**


1. National Institute for Occupational Safety and Health (NIOSH), "NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012." Available at http://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf. Accessed January 21, 2013.
2. www.uptodate.com: Ganirelix: Drug Information.
3. www.epocrates.com: ganirelix acetate Drug information.


**REVISION HISTORY:**

Date Reviewed/No Updates: 1/13/15 by C. Sanders, MD
Date Approved by P&T Committee: 1/27/15
Date Reviewed/Updated: 3/24/15 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/26/16
Date Reviewed/No Updates: 1/24/17 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/24/17
Date Reviewed/Archived: 1/1/18 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/23/18
Date Reviewed/No Updates/Date Unarchived: 1/22/19 by C. Sanders, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/22/19
Date Reviewed/No Updates: 2/18/20 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/18/20
Date Reviewed/No Updates: 2/2/21 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/2/21
Date Reviewed/No Updates: 2/1/22 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 2/1/22
Date Reviewed/No Updates: 1/31/23 by H. Taekman, MD; R. Sterling, MD
Date Approved by P&T Committee: 1/31/23

| Revision Date | Content Revised (Yes/No) | Contributors | Review/Revision Notes |
|---|---|---|---|
| 1/24/17 | No | Catherine Sanders, MD; Robert Sterling, MD | Annual review |
| 1/1/18 | No | Catherine Sanders, MD; Robert Sterling, MD | Archived – excluded from the Formulary effective 1/1/18 |
| 1/22/19 | Yes | Catherine Sanders, MD; Robert Sterling, MD | Unarchived – Formulary Exclusion – For Exception |

| | | | |
|---|---|---|---|
| | | | Review Use Only<br>Annual Review |
| 2/18/20 | No | Howard Taekman, MD; Robert Sterling, MD | Annual review |
| 2/2/21 | No | Howard Taekman, MD; Robert Sterling, MD | Annual review |
| 2/1/22 | No | Howard Taekman, MD; Robert Sterling, MD | Annual review |
| 1/31/23 | No | Howard Taekman, MD; Robert Sterling, MD | Annual review |